LIVE PODCAST

Will New Antibody Drug Conjugates (ADCs) Cure Bladder Cancer?





Thomas Powles, MBBS, MRCP, MD

University of London and Barts Cancer Centre



Andrea Apolo, MD National Institutes of Health



Petros Grivas, MD, PhD University of Washington



Shilpa Gupta, MD Cleveland Clinic




Kala Sridhar, MD Princess Margaret Cancer Center

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Govitecan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301,302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum-refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		The Ur () migos"


1968P

Study EV-103 Dose Escalation/Cohort A (DE/A): 5y Follow-Up of First-Line (1L) Enfortumab Vedotin (EV) + Pembrolizumab (P) in Cisplatin (Cis)-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (Ia/mUC)


Jonathan E. Rosenberg¹, Peter H. O' Donnell², Daniel Petrylak³, Thomas W. Flaig⁴, Christopher J. Hoimes⁵, Shilpa Gupta⁶, Nataliya Mar⁷, Terence W. Friedlander⁸, Scott Tagawa⁹, Mehmet Asim Bilen¹⁰, Jason Brown¹¹, Rana R. McKay¹², Jaime R. Merchan¹³, Sandy Srinivas¹⁴, Aditya Shetty¹⁵, Blanca Homet Moreno¹⁶, Griffith Davis¹⁷, Heidi S. Wirtz¹⁷, Yalin Zhu¹⁷, Matthew I. Milowsky¹⁸



NECTIN-4 as a biomarker for enfortumab vedotin and pembrolizumab vs chemotherapy in the EV302 study.




Consistent PFS Benefit with EV+P Across Nectin-4 and PD-L1 Subgroups



Data cutoff: 8 August 2023.

CPS, combined positive score; EV, enfortumab vedotin; P, pembrolizumab; PD-L1, programmed death ligand 1. ^aThe median Nectin-4 H-score was 275 across patients in both arms. ^bCPS <10. ^oCPS ≥10.

NECTIN-4 amplification and response to EV monotherapy



Neoadjuvant durvalumab/tremelimumab/enfortumab vedotin resulting in high ctDNA clearance



- At baseline, the overall ctDNA-positive rate was 62.5% (10/16 patients) and the overall ctDNA-negative rate was 37.5% (6/16 patients)
- After neoadjuvant treatment, the pre-RC ctDNA-negative rate was 78.6% (11/14 patients)
- A total of 7 out of 10 patients had ctDNA clearance (baseline ctDNA positive, then pre-RC ctDNA negative)


6

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Govitecan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301,302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum-refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		The Ur () migos


Sacituzumab Govitecan alone and with PD-1 therapy

4 cycles of neoadjuvant therapy was associated with responses but also 8% treatment-related deaths


	Median follow-up: 7.1 months
Outcome	N (%)
Total N=11 RC-evaluab	le patients
 ypT0N0 (95%CI) 	4 (36.4; 14.9–64.8)
 ypT≤1N0 (95%CI) 	5 (45.4; 21.2–72.0)
Total N=21 ITT pa	tients
 ypT0N0-x (95%Cl) 	10 (47.6; 28.3–67.6)
 ypT≤1N0-x 	11 (52.4)
 ypT2Nx^a 	1 (4.7)
 ypT3-4N0^b 	3 (14.3)
• ypT _{any} N+ ^b	3 (14.3)
Relapse/progression during or post-SG	1 (4.7)



Platinum refractory UC combination with PD1 inhibitor



Enfortumab vedotin with Sacituzumab vedotin in pretreated advanced urothelial cancer



One patient who did not undergo any post-baseline scans was marked as having 0 percentage change.

* One patient experienced progressive disease due to the emergence of a new non-target lesion, despite the reduction in a target lesion.
 ** Among three patients with complete response, two had lymph node lesions and the sum of lesions was not zero for those achieving a complete response.

Best % Change in Tumor Measurements


McGregor B **ESMO 23**

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Govitecan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301, 302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum-refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		

[®]Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials

Xinan Sheng, MD¹ ([®]); Lin Wang, MD²; Zhisong He, MD³; Yanxia Shi, MD⁴; Hong Luo, MD⁵; Weiqing Han, MD⁶; Xin Yao, MD⁷; Benkang Shi, MD⁸; Jiyan Liu, MD⁹ ([®]); Changlu Hu, MD¹⁰; Ziling Liu, MD¹¹; Hongqian Guo, MD¹² ([®]); Guohua Yu, MD¹³; Zhigang Ji, MD¹⁴; Jianming Ying, MD¹⁵ ([®]); Yun Ling, MD¹⁶; Shiying Yu, MD¹⁶; Yi Hu, MD¹⁷; Jianming Guo, MD¹⁸; Jianmin Fang, PhD^{19,20} ([®]); Aiping Zhou, MD²; and Jun Guo, MD¹ ([®])

DOI https://doi.org/10.1200/JC0.22.02912




Sheng X et al. *J Clin Oncol*. Published online November 21, 2023. doi:10.1200/JCO.22.02912

	C005 (N=43)	C009 (N=64)	Pooled (N=107)
HER2-Positive IHC3+ or 2+/FISH+	60%	64%	62.2%
HER2-Low IHC2+/FISH- IHC2+/FISH Unknown	40% 66%	39.4% 50%	39.6% 55.6%


Most frequent TRAE All grades (≥30%)						
Any event	100%					
Peripheral sensory neuropathy	68%					
Leukopenia	51%					
AST increase	42%					
Neutropenia	42%					
Alopecia	40%					
Asthenia	39%					
ALT increase	36%					
Decreased appetite	32%					

Disitamab Vedotin plus Toripalimab in muscle invasive bladder cancer (MIBC): data on 31/47 patients

Pathologic Response	Evaluable Patients N=31
pCR (ypT0N0), n (%)	19 (61.3)
95% CI	42.2, 78.2
pPR (<ypt2, (%)<="" and="" n="" n0),="" td=""><td>23 (74.2)</td></ypt2,>	23 (74.2)
95% CI	55.4, 88.1




- The median event-free survival (EFS) follow-up was 5.4 months. The median EFS not yet mature and EFS rate at 12 months was 85.0% (95%CI: 64.0%, 94.0%).
- The median DFS and OS not yet mature and will be reported later.



Xinan Sheng, MD

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Govitecan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301,302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		

A Phase 2 study of T-DXd in patients with HER2-expressing solid tumours in 2L and later patient population



ILD/pneumoni	tis adjudicated a	s T-DXd-related	L.			
n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
All patients (N=267)	6 (2.2)	12 (4.5)	1 (0.4)	0	1 (0.4)	20 (7.5)
Left ventricula	r dysfunction ^a					
n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any grade
Ejection fraction	decreased					
All patients (N=267)	1 (0.4)	4 (1.5)	1 (0.4)	0	0	7 (2.6) ^b
Cardiac failure						
All patients (N=267)	0	0	1 (0.4)	0	0	1 (1.04)




1. Meric-Bernstam, ASCO 2023 (Oral presentation; Abstract LBA3000)

Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Govitecan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301,302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum-refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		The Ur () migos

BT8009 (zelenectide pevedotin) = peptide drug conjugate







- Small conjugated molecule
- Short linear peptides into a stabilized bi-cyclic structure using a central chemical scaffold
- BT-8009 can quickly leave the vasculature and distribute rapidly to target tissues and tumors, enabling delivery directly to the required site of action

	Patients* (N=45)							
Event type	Grade 1, n (%)	Grade 2, n (%)	Grade 3, n (%)	Grade 4, n (%)	Grade 5, n (%)	Total, n (%)		
Peripheral neuropathy ^b Peripheral sensory neuropathy ^c	9 (20) 6 (13)	7 (16) 0	0	0	0 0	16 (36) 6 (13)		
Hyperglycemia ^c /diabetes mellitus ^c	2 (4)	0	1 (2)	0	0	3 (7)		
Skin reactions ^d	6 (13)	2 (4)	0	0	0	8 (18)		
Neutropenia	2 (4)	2 (4)	2(4)	0	0	6 (13)		
Eye disorders*	2 (4)	1 (2)	0	0	0	3 (7)		

Torras et al. ESMO 2024



DURAVELO-2 STUDY (NCT04561362)



Loriot et al, ASCO 2024

ADC in platinum advanced bladder cancer	Enfortumab Vedotin	Sacituzumab Goveitcan (n=113)	Disitamab Vedotin (n=109)	T-DXD (n=16)	BT8009 (n=45)	BL-B01D1 (n=27)
Target	NECTIN-4	TROP-2	HER-2	HER-2	NECTIN-4	HER3/EGFR
Payload	MMAE	TOPO-1	MMAE	TOPO-1	MMAE	TOPO-1
Biomarker selection	None	None	1-3+	3+	None	None
Randomised phase III studies	301,302,303,304 VOLGA	TROPICS-4	1st line R3 (China and Global)	None	1st line R3 Global	Planned (China)
Grade 3+ TRAEs	51%	65%	45%	45-55%	22%	52%
Response rates in platinum-refractory disease	41%	28%	50%	56%	45%	41%
Response rates in combination with PD-1 therapy	68% (420)	34% (41)	75% (20)	36% (26)		The Ur () migos



BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)

Dingwei Ye¹


Xiaojie Bian¹, Tiejun Yang², Shusuan Jiang³, Manming Cao⁴, Sa Xiao⁵, Hongwei Wang⁶, Hai Zhu⁶, Yi Zhu²

- ¹ Urinary surgery, Fudan University Shanghai Cancer Center, Shanghai, China;
- ² Urinary surgery, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China;
- ³ Urinary surgery, Hunan Cancer Hospital, Changsha, China;
- ⁴ Breast Oncology Dept., Zhujiang Hospital of Southern Medical University, Guangzhou, China;
- ⁵ Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., Chengdu, China; ⁶ SystImmune Inc., Redmond, United States of America; ⁷ Sichuan Biokin Pharmaceutical Co., Ltd, Chengdu, China

Shanghai, China 9/13/2024


Depth and Duration of Response

Patients at 2.2 mg/kg D1D8 Q3W (N=27)





Where to explore new ADC



Audience Question

Which of the following is likely to have the biggest impact on bladder cancer care in the future?

- 1. Sacituzumab Govitecan
- 2. Disitamab Vedotin
- 3. T-DXD
- 4. BT8009 (bicycle)
- 5. BL-BO1D1 (HER3/EGFR)
- 6. D-DXD or another TROP-2 ADC

